Trials / Unknown
UnknownNCT04397770
Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma
Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma：a Single-center, Exploratory Clinical Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
It is a single-center,exploratory clinical trial aimed to evaluate the objective response rate (ORR) of Camrelizumab combined with apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR1210 | SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody |
| DRUG | apatinib mesylate | apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2). |
| DRUG | Temozolomide Injection | Temozolomide is an imidazole tetrazine derivative of the alkylating agent dacarbazine.Temozolomide is not directly active but undergoes rapid, spontaneous, non-enzymatic conversion at physiologic pH to the cytotoxic compound, monomethyl triazeno imidazole carboxamide (MTIC). |
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2022-06-01
- Completion
- 2023-02-01
- First posted
- 2020-05-21
- Last updated
- 2020-05-21
Source: ClinicalTrials.gov record NCT04397770. Inclusion in this directory is not an endorsement.